Prevalence and features of asthma-COPD overlap in the United States 2007-2012

Angelico Mendy, Erick Forno, Theophile Niyonsenga, Ryan Carnahan, Janvier Gasana

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co‐exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma‐COPD overlap (ACO) in the US population. Aims To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO. Methods Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post‐bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7. Results Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age‐standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%–1.26%) and 1.05% (0.74%–1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non‐Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48–8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17–24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone. Conclusion Age‐adjusted prevalence of ACO in the United States was 1.05% in 2007–2012, representing 0.94 (95% CI: 0.62–1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.
Original languageEnglish
Pages (from-to)2369-2377
Number of pages9
JournalClinical Respiratory Journal
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2018

Cite this

Mendy, Angelico ; Forno, Erick ; Niyonsenga, Theophile ; Carnahan, Ryan ; Gasana, Janvier. / Prevalence and features of asthma-COPD overlap in the United States 2007-2012. In: Clinical Respiratory Journal. 2018 ; Vol. 12, No. 8. pp. 2369-2377.
@article{01094f571d414dbf84bb9d860d44685e,
title = "Prevalence and features of asthma-COPD overlap in the United States 2007-2012",
abstract = "Background Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co‐exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma‐COPD overlap (ACO) in the US population. Aims To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO. Methods Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post‐bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7. Results Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age‐standardized ACO prevalence were, respectively, 0.96{\%} (95{\%} CI: 0.65{\%}–1.26{\%}) and 1.05{\%} (0.74{\%}–1.37{\%}). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non‐Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95{\%} CI: 1.48–8.06]) and oxygen therapy in COPD (OR = 11.17, 95{\%} CI: 5.17–24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone. Conclusion Age‐adjusted prevalence of ACO in the United States was 1.05{\%} in 2007–2012, representing 0.94 (95{\%} CI: 0.62–1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.",
keywords = "ACO, ACOS, asthma, asthma-COPD overlap, COPD, prevalence",
author = "Angelico Mendy and Erick Forno and Theophile Niyonsenga and Ryan Carnahan and Janvier Gasana",
year = "2018",
month = "8",
doi = "10.1111/crj.12917",
language = "English",
volume = "12",
pages = "2369--2377",
journal = "Clinical Respiratory Journal",
issn = "1752-699X",
publisher = "Wiley-Blackwell",
number = "8",

}

Prevalence and features of asthma-COPD overlap in the United States 2007-2012. / Mendy, Angelico; Forno, Erick; Niyonsenga, Theophile; Carnahan, Ryan; Gasana, Janvier.

In: Clinical Respiratory Journal, Vol. 12, No. 8, 08.2018, p. 2369-2377.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence and features of asthma-COPD overlap in the United States 2007-2012

AU - Mendy, Angelico

AU - Forno, Erick

AU - Niyonsenga, Theophile

AU - Carnahan, Ryan

AU - Gasana, Janvier

PY - 2018/8

Y1 - 2018/8

N2 - Background Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co‐exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma‐COPD overlap (ACO) in the US population. Aims To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO. Methods Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post‐bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7. Results Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age‐standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%–1.26%) and 1.05% (0.74%–1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non‐Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48–8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17–24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone. Conclusion Age‐adjusted prevalence of ACO in the United States was 1.05% in 2007–2012, representing 0.94 (95% CI: 0.62–1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.

AB - Background Perceived to be distinct, asthma and chronic obstructive pulmonary disease (COPD) can co‐exist and potentially have a worse prognosis than the separate diseases. Yet, little is known about the exact prevalence and the characteristics of the Asthma‐COPD overlap (ACO) in the US population. Aims To determine ACO prevalence in the United States, identify ACO predictors, examine ACO association with asthma and COPD severity, and describe distinctive spirometry and laboratory features of ACO. Methods Data on adult participants to the National Health and Nutrition Examination Surveys conducted from 2007 to 2012 was analyzed. ACO was defined as current asthma and post‐bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7. Results Overall, 7,570 participants representing 98.58 million Americans were included in our study. From 2007 to 2012, the crude and age‐standardized ACO prevalence were, respectively, 0.96% (95% CI: 0.65%–1.26%) and 1.05% (0.74%–1.37%). In asthma, ACO predictors included older age, male gender, and smoking. In COPD, ACO predictors were non‐Hispanic Black race/ethnicity and obesity. ACO was associated with increased ER visits for asthma (OR = 3.46, 95% CI: 1.48–8.06]) and oxygen therapy in COPD (OR = 11.17, 95% CI: 5.17–24.12]). In spirometry, FEV1 and peak expiratory flow were lower in ACO than in asthma or COPD alone. Conclusion Age‐adjusted prevalence of ACO in the United States was 1.05% in 2007–2012, representing 0.94 (95% CI: 0.62–1.26) million Americans. It is much lower than previously reported. The overlap was associated with higher asthma and COPD severity as well as decreased lung function compared with COPD or asthma alone.

KW - ACO

KW - ACOS

KW - asthma

KW - asthma-COPD overlap

KW - COPD

KW - prevalence

U2 - 10.1111/crj.12917

DO - 10.1111/crj.12917

M3 - Article

VL - 12

SP - 2369

EP - 2377

JO - Clinical Respiratory Journal

JF - Clinical Respiratory Journal

SN - 1752-699X

IS - 8

ER -